Drug intelligence / Profile preview

VX-409

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

VX-409 is a small molecule, subtype-selective sodium channel modulator developed by Vertex Pharmaceuticals in collaboration with GSK for the treatment of pain. Specifically targeted at inflammatory and neuropathic pain, the compound was designed to selectively inhibit voltage-gated sodium channels (Nav) involved in pain signaling while avoiding the side effects associated with non-selective blockers. VX-409 entered Phase I clinical trials in early 2007; however, development was subsequently discontinued, and the partnership shifted focus toward backup compounds within the same chemical series.

Targets

SCN8A (NaV1.6)

Beyond the preview

Go deeper on VX-409.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VX-409.

Explore the full profile